BR112016009809A2 - composições de fosfato de cálcio amorfo substituído por magnésio e seus usos - Google Patents

composições de fosfato de cálcio amorfo substituído por magnésio e seus usos

Info

Publication number
BR112016009809A2
BR112016009809A2 BR112016009809A BR112016009809A BR112016009809A2 BR 112016009809 A2 BR112016009809 A2 BR 112016009809A2 BR 112016009809 A BR112016009809 A BR 112016009809A BR 112016009809 A BR112016009809 A BR 112016009809A BR 112016009809 A2 BR112016009809 A2 BR 112016009809A2
Authority
BR
Brazil
Prior art keywords
calcium phosphate
magnesium
phosphate compositions
substituted
amorphous
Prior art date
Application number
BR112016009809A
Other languages
English (en)
Portuguese (pt)
Inventor
THOMAS-MCKAY Emma
Joseph Powell Jonathan
PELE Laetitia
Jorge Rodrigues Faria Nuno
HEWITT Rachel
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of BR112016009809A2 publication Critical patent/BR112016009809A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
BR112016009809A 2013-11-05 2014-11-05 composições de fosfato de cálcio amorfo substituído por magnésio e seus usos BR112016009809A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Publications (1)

Publication Number Publication Date
BR112016009809A2 true BR112016009809A2 (pt) 2017-12-05

Family

ID=49767709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009809A BR112016009809A2 (pt) 2013-11-05 2014-11-05 composições de fosfato de cálcio amorfo substituído por magnésio e seus usos

Country Status (16)

Country Link
US (1) US10596122B2 (cg-RX-API-DMAC7.html)
EP (1) EP3065715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016537408A (cg-RX-API-DMAC7.html)
KR (1) KR20160079060A (cg-RX-API-DMAC7.html)
CN (1) CN105722504A (cg-RX-API-DMAC7.html)
AU (1) AU2014345334B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016009809A2 (cg-RX-API-DMAC7.html)
CA (1) CA2929123A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690659A1 (cg-RX-API-DMAC7.html)
ES (1) ES2761559T3 (cg-RX-API-DMAC7.html)
GB (1) GB201319548D0 (cg-RX-API-DMAC7.html)
IL (1) IL245380B (cg-RX-API-DMAC7.html)
MX (1) MX367473B (cg-RX-API-DMAC7.html)
SG (2) SG10201803562YA (cg-RX-API-DMAC7.html)
WO (1) WO2015067939A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602906B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
FR3021045B1 (fr) * 2014-05-16 2020-02-21 Solvay Sa Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1
CN110573455A (zh) * 2017-04-27 2019-12-13 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
WO2021003601A1 (zh) * 2019-07-05 2021-01-14 广州中大医疗器械有限公司 一种新型可载药微球及其制备方法
WO2021086252A1 (en) 2019-10-30 2021-05-06 Psilox Ab Stabilized amorphous calcium magnesium phosphate particle compositions
CN116768175B (zh) * 2023-07-01 2025-12-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
KR20260019884A (ko) * 2024-08-02 2026-02-10 한국과학기술연구원 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
EP1872798B1 (en) 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
EP2106217B1 (en) 2006-12-12 2019-03-13 Firmenich S.A. Active ingredient delivery system with an amorphous metal salt as carrier
US20120128767A1 (en) * 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Also Published As

Publication number Publication date
US10596122B2 (en) 2020-03-24
MX2016005415A (es) 2017-03-01
AU2014345334B2 (en) 2019-10-31
ZA201602906B (en) 2019-09-25
EA201690659A1 (ru) 2016-10-31
MX367473B (es) 2019-08-23
IL245380A0 (en) 2016-06-30
WO2015067939A1 (en) 2015-05-14
ES2761559T3 (es) 2020-05-20
US20160235683A1 (en) 2016-08-18
GB201319548D0 (en) 2013-12-18
IL245380B (en) 2019-02-28
KR20160079060A (ko) 2016-07-05
EP3065715B1 (en) 2019-10-02
AU2014345334A1 (en) 2016-05-19
JP2016537408A (ja) 2016-12-01
EP3065715A1 (en) 2016-09-14
JP2020073467A (ja) 2020-05-14
CA2929123A1 (en) 2015-05-14
SG11201603261PA (en) 2016-05-30
SG10201803562YA (en) 2018-06-28
CN105722504A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
MX2016005415A (es) Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos.
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CO6831973A2 (es) Composición inmunogénica para modulación del sistema inmune y su uso, método de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune
LT3444261T (lt) Metilbardoksolono 2,2-difluorpropionamido darinys, jo farmacinės kompozicijos ir polimorfai, skirti panaudoti tam tikrų ligų gydymui
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2013011421A (es) Derivados de pirazolo-pirimidina.
BR112016003293A8 (pt) Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
BR112017002335A2 (pt) formulações de suspensão oral em pó de agentes antibacterianos
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
BRPI1016208A2 (pt) implante e composição terapêutica para o tratamento de lesões e/ou doenças relacionadas ao sistema musculoesquelético humano e/ou animal
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
SI3052144T1 (sl) Sistem za pranje, razkuževanje in/ali sterilizacijo medicinskih, zobozdravstvenih, laboratorijskih in/ali farmacevtskih izdelkov
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
BR112016009076A2 (pt) Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano
Strus et al. Research sapropel’s property of the pribich
FR2980360B1 (fr) Utilisation cosmetique de l'hesperidine ou de l'un de ses derives dans la prevention et/ou le traitement des odeurs corporelles.
Mitichkina et al. Leukocyte elastase, alpha 1-proteinase inhibitor and C-reactive protein in patients with delayed negativation of serological reactions after treatment of early syphilis
BR112015030569A8 (pt) usos de compostos anti-fibrogênico, e composição farmacêutica compreendendo compostos anti-fibrogênico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements